Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Recruiting
NCT06514534Phase 2Updated Apr 21, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML)
France
Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.Completed
NCT03275064Phase 2Updated Apr 21, 2026
Sponsor: Novartis Pharmaceuticals
Osteoarthritis
United States, Czechia, Denmark
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.Completed
NCT03578367Phase 2Updated Apr 21, 2026
Sponsor: Novartis Pharmaceuticals
CML · Chronic Myelogenous Leukemia · Leukemia, Myeloid Chronic · Hematologic Diseases
United States, Austria, Canada, Czechia, Denmark +10 more
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).Completed
NCT01682083Phase 3Updated Apr 21, 2026
Sponsor: Novartis Pharmaceuticals
Melanoma
United States, Argentina, Australia, Austria, Belgium +20 more
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)Not Yet Recruiting
NCT07538401Phase 2Updated Apr 20, 2026
Sponsor: University Health Network, Toronto
Chronic Myeloid Leukemia (CML) in
Asciminib RMP StudyRecruiting
NCT05943522N/AUpdated Apr 20, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia
South Korea
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTETerminated
NCT05171075Phase 3Updated Apr 17, 2026
Sponsor: Anthos Therapeutics, Inc.
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolism
United States, Australia, Austria, Canada, China +15 more
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaActive Not Recruiting
NCT05888493Phase 3Updated Apr 17, 2026
Sponsor: Novartis Pharmaceuticals
Follicular Lymphoma (FL)
Australia, Austria, Canada, Czechia, Hungary +6 more
Assessment of the Impact of Clinical Decision Support Systems Included in Electronic Health RecordsCompleted
NCT06248658N/AUpdated Apr 17, 2026
Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Chronic Heart Failure (CHF)
Russia
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian FederationActive Not Recruiting
NCT06517732N/AUpdated Apr 16, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Russia
Remibrutinib in Real-world Clinical PracticeRecruiting
NCT07358364N/AUpdated Apr 16, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
United States
Ribociclib (LEE011) Rollover Study for Continued AccessActive Not Recruiting
NCT02934568Phase 2Updated Apr 16, 2026
Sponsor: Novartis Pharmaceuticals
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
United States, France, Germany, Singapore, Spain +1 more
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world SettingCompleted
NCT05362903N/AUpdated Apr 16, 2026
Sponsor: Novartis Pharmaceuticals
Hypercholesterolemia
Germany
Heart Map Study -Determination of Myocardial Relaxation Times Values in Healthy VoluntersCompleted
NCT01712581NAUpdated Apr 16, 2026
Sponsor: University Hospital, Rouen
Normal Myocardial T1, T2 and T2* Values
France
Managed Access Programs for ETB115, EltrombopagAvailable
NCT04837703N/AUpdated Apr 15, 2026
Sponsor: Novartis Pharmaceuticals
Thrombocytopenia
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)Terminated
NCT04737330Phase 3Updated Apr 15, 2026
Sponsor: Novartis Pharmaceuticals
Thyroid Eye Disease · Graves Orbitopathy
Germany
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCompleted
NCT04028245EARLY_Phase 1Updated Apr 15, 2026
Sponsor: Columbia University
Carcinoma, Renal Cell
United States
A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in ChinaCompleted
NCT07450170N/AUpdated Apr 15, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Urticaria
China
Managed Access Programs for BYL719, AlpelisibAvailable
NCT04085653N/AUpdated Apr 14, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-Related Overgrowth Spectrum (PROS) · Breast Cancer
Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol ControlCompleted
NCT05622929NAUpdated Apr 14, 2026
Sponsor: Hospital Israelita Albert Einstein
Cardiovascular Diseases · Atherosclerosis · Dyslipidemias
Brazil
Managed Access Programs for SEG101, CrizanlizumabAvailable
NCT03720626N/AUpdated Apr 14, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With HypercholesterolemiaCompleted
NCT05192941Phase 4Updated Apr 14, 2026
Sponsor: Novartis Pharmaceuticals
Hypercholesterolemia
Bulgaria, Czechia, Estonia, France, Germany +3 more
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational StudyCompleted
NCT05285904N/AUpdated Apr 14, 2026
Sponsor: Novartis Pharmaceuticals
Multiple Sclerosis
Switzerland
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG CriteriaTerminated
NCT01642017Phase 1Updated Apr 14, 2026
Sponsor: Institut Claudius Regaud
Metastatic Cancer (Different Solid Tumour Types)
France
Secondary Use of PARALLEL-HF DataCompleted
NCT07527767N/AUpdated Apr 14, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Japan

Previous page Next page